APO Research
Talk to an analyst

APO RESEARCH · REPORT

Microbiome Drugs

Microbiome Drug is a kind of medicine made with microorganisms. According to the source, it is divided into three categories: drugs derived from whole or part of microorganisms, drugs derived from microbial primary metabolites, and drugs derived from microbial secondary metabolites.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Microbiome Drug is a kind of medicine made with microorganisms. According to the source, it is divided into three categories: drugs derived from whole or part of microorganisms, drugs derived from microbial primary metabolites, and drugs derived from microbial secondary metabolites.

Selected research

Market Analysis & Forecast

Global Microbiome Drugs Market Analysis and Forecast 2026-2032

30 December 2025206 pages

Choose your research edition.

Industry ResearchMicrobiome Drugs Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Microbiome Drugs Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Microbiome Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Microbiome Drugs Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Microbiome Drugs Market Analysis and Forecast 2026-2032206 pages · $4,950 USD

Market perspective

Microbiome Drug is a kind of medicine made with microorganisms. According to the source, it is divided into three categories: drugs derived from whole or part of microorganisms, drugs derived from microbial primary metabolites, and drugs derived from microbial secondary metabolites.

North America and Europe hold most of market share of microbiome drugs, and North America occupies a share over 77%, on the other hand, Europe takes a share of over 22% in total. Global core microbiome drugs manufacturers include Seres Therapeutics, Assembly Biosciences, Synthetic Biologics etc.

Report Includes

Read the full market overview

This report presents an overview of global market for Microbiome Drugs, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Microbiome Drugs, also provides the revenue of main regions and countries. Of the upcoming market potential for Microbiome Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Microbiome Drugs revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Microbiome Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Microbiome Drugs revenue, projected growth trends, production technology, application and end-user industry.

Microbiome Drugs Segment by Company

Seres Therapeutics

Assembly Biosciences

Synthetic Biologics

Interxon

PureTech

Synlogic

Enterome BioScience

4D Pharma

Second Genome

AOBiome

Rebiotix

Metabiomics

Ritter Pharmaceuticals

Symberix

OpenBiome

Azitra

Osel

Microbiome Drugs Segment by Type

Oral Dosage Form

Enteric Capsules

Microbiome Drugs Segment by Symptom

Gastrointestinal Disorders

Autoimmune Disorders

Diabetes

Cancer

Others

Microbiome Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Microbiome Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Microbiome Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Microbiome Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Microbiome Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Microbiome Drugs company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Microbiome Drugs revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Microbiome Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Oral Dosage Form Major Player Table 3. Enteric Capsules Major Player Table 4. Global Microbiome Drugs Market Size Growth Rate by Symptom (US$ Million), 2021 VS 2025 VS 2032 Table 5. Gastrointestinal Disorders Major Player Table 6. Autoimmune Disorders Major Player Table 7. Diabetes Major Player Table 8. Cancer Major Player Table 9. Others Major Player Table 10. Microbiome Drugs Industry Trends Table 11. Microbiome Drugs Industry Drivers Table 12. Microbiome Drugs Industry Opportunities and Challenges Table 13. Microbiome Drugs Industry Restraints Table 14. Global Microbiome Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Microbiome Drugs Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Microbiome Drugs Market Share by Region (2021-2026) Table 17. Global Microbiome Drugs Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Microbiome Drugs Market Share by Region (2027-2032) Table 19. Global Microbiome Drugs Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Microbiome Drugs Revenue Market Share by Players (2021-2026) Table 21. Global Microbiome Drugs Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Microbiome Drugs Key Players Headquarters & Area Served Table 23. Global Microbiome Drugs Players, Product Type & Application Table 24. Global Microbiome Drugs Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Microbiome Drugs by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Microbiome Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Microbiome Drugs Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Microbiome Drugs Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Microbiome Drugs Revenue Market Share by Type (2021-2026) Table 31. Global Microbiome Drugs Revenue Market Share by Type (2027-2032) Table 32. Global Microbiome Drugs Revenue by Symptom 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Microbiome Drugs Revenue by Symptom (2021-2026) & (US$ Million) Table 34. Global Microbiome Drugs Revenue by Symptom (2027-2032) & (US$ Million) Table 35. Global Microbiome Drugs Revenue Market Share by Symptom (2021-2026) Table 36. Global Microbiome Drugs Revenue Market Share by Symptom (2027-2032) Table 37. Seres Therapeutics Company Information Table 38. Seres Therapeutics Business Overview Table 39. Seres Therapeutics Microbiome Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Seres Therapeutics Microbiome Drugs Product Portfolio Table 41. Seres Therapeutics Recent Development Table 42. Assembly Biosciences Company Information Table 43. Assembly Biosciences Business Overview Table 44. Assembly Biosciences Microbiome Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Assembly Biosciences Microbiome Drugs Product Portfolio Table 46. Assembly Biosciences Recent Development Table 47. Synthetic Biologics Company Information Table 48. Synthetic Biologics Business Overview Table 49. Synthetic Biologics Microbiome Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Synthetic Biologics Microbiome Drugs Product Portfolio Table 51. Synthetic Biologics Recent Development Table 52. Interxon Company Information Table 53. Interxon Business Overview Table 54. Interxon Microbiome Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Interxon Microbiome Drugs Product Portfolio Table 56. Interxon Recent Development Table 57. PureTech Company Information Table 58. PureTech Business Overview Table 59. PureTech Microbiome Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. PureTech Microbiome Drugs Product Portfolio Table 61. PureTech Recent Development Table 62. Synlogic Company Information Table 63. Synlogic Business Overview Table 64. Synlogic Microbiome Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Synlogic Microbiome Drugs Product Portfolio Table 66. Synlogic Recent Development Table 67. Enterome BioScience Company Information Table 68. Enterome BioScience Business Overview Table 69. Enterome BioScience Microbiome Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Enterome BioScience Microbiome Drugs Product Portfolio Table 71. Enterome BioScience Recent Development Table 72. 4D Pharma Company Information Table 73. 4D Pharma Business Overview Table 74. 4D Pharma Microbiome Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. 4D Pharma Microbiome Drugs Product Portfolio Table 76. 4D Pharma Recent Development Table 77. Second Genome Company Information Table 78. Second Genome Business Overview Table 79. Second Genome Microbiome Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Second Genome Microbiome Drugs Product Portfolio Table 81. Second Genome Recent Development Table 82. AOBiome Company Information Table 83. AOBiome Business Overview Table 84. AOBiome Microbiome Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. AOBiome Microbiome Drugs Product Portfolio Table 86. AOBiome Recent Development Table 87. Rebiotix Company Information Table 88. Rebiotix Business Overview Table 89. Rebiotix Microbiome Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Rebiotix Microbiome Drugs Product Portfolio Table 91. Rebiotix Recent Development Table 92. Metabiomics Company Information Table 93. Metabiomics Business Overview Table 94. Metabiomics Microbiome Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Metabiomics Microbiome Drugs Product Portfolio Table 96. Metabiomics Recent Development Table 97. Ritter Pharmaceuticals Company Information Table 98. Ritter Pharmaceuticals Business Overview Table 99. Ritter Pharmaceuticals Microbiome Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Ritter Pharmaceuticals Microbiome Drugs Product Portfolio Table 101. Ritter Pharmaceuticals Recent Development Table 102. Symberix Company Information Table 103. Symberix Business Overview Table 104. Symberix Microbiome Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Symberix Microbiome Drugs Product Portfolio Table 106. Symberix Recent Development Table 107. OpenBiome Company Information Table 108. OpenBiome Business Overview Table 109. OpenBiome Microbiome Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. OpenBiome Microbiome Drugs Product Portfolio Table 111. OpenBiome Recent Development Table 112. Azitra Company Information Table 113. Azitra Business Overview Table 114. Azitra Microbiome Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Azitra Microbiome Drugs Product Portfolio Table 116. Azitra Recent Development Table 117. Osel Company Information Table 118. Osel Business Overview Table 119. Osel Microbiome Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Osel Microbiome Drugs Product Portfolio Table 121. Osel Recent Development Table 122. North America Microbiome Drugs Revenue by Type (2021-2026) & (US$ Million) Table 123. North America Microbiome Drugs Revenue by Type (2027-2032) & (US$ Million) Table 124. North America Microbiome Drugs Revenue by Symptom (2021-2026) & (US$ Million) Table 125. North America Microbiome Drugs Revenue by Symptom (2027-2032) & (US$ Million) Table 126. North America Microbiome Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 127. North America Microbiome Drugs Revenue by Country (2021-2026) & (US$ Million) Table 128. North America Microbiome Drugs Revenue by Country (US$ Million) & (2027-2032) Table 129. Europe Microbiome Drugs Revenue by Type (2021-2026) & (US$ Million) Table 130. Europe Microbiome Drugs Revenue by Type (2027-2032) & (US$ Million) Table 131. Europe Microbiome Drugs Revenue by Symptom (2021-2026) & (US$ Million) Table 132. Europe Microbiome Drugs Revenue by Symptom (2027-2032) & (US$ Million) Table 133. Europe Microbiome Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 134. Europe Microbiome Drugs Revenue by Country (2021-2026) & (US$ Million) Table 135. Europe Microbiome Drugs Revenue by Country (US$ Million) & (2027-2032) Table 136. China Microbiome Drugs Revenue by Type (2021-2026) & (US$ Million) Table 137. China Microbiome Drugs Revenue by Type (2027-2032) & (US$ Million) Table 138. China Microbiome Drugs Revenue by Symptom (2021-2026) & (US$ Million) Table 139. China Microbiome Drugs Revenue by Symptom (2027-2032) & (US$ Million) Table 140. Asia Microbiome Drugs Revenue by Type (2021-2026) & (US$ Million) Table 141. Asia Microbiome Drugs Revenue by Type (2027-2032) & (US$ Million) Table 142. Asia Microbiome Drugs Revenue by Symptom (2021-2026) & (US$ Million) Table 143. Asia Microbiome Drugs Revenue by Symptom (2027-2032) & (US$ Million) Table 144. Asia Microbiome Drugs Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 145. Asia Microbiome Drugs Revenue by Region (US$ Million) & (2021-2026) Table 146. Asia Microbiome Drugs Revenue by Region (US$ Million) & (2027-2032) Table 147. SAMEA Microbiome Drugs Revenue by Type (2021-2026) & (US$ Million) Table 148. SAMEA Microbiome Drugs Revenue by Type (2027-2032) & (US$ Million) Table 149. SAMEA Microbiome Drugs Revenue by Symptom (2021-2026) & (US$ Million) Table 150. SAMEA Microbiome Drugs Revenue by Symptom (2027-2032) & (US$ Million) Table 151. SAMEA Microbiome Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 152. SAMEA Microbiome Drugs Revenue by Country (2021-2026) & (US$ Million) Table 153. SAMEA Microbiome Drugs Revenue by Country (US$ Million) & (2027-2032) Table 154. Research Programs/Design for This Report Table 155. Authors List of This Report Table 156. Secondary Sources Table 157. Primary Sources List of Figures Figure 1. Microbiome Drugs Image Figure 2. Global Microbiome Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Microbiome Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Oral Dosage Form Image Figure 5. Enteric Capsules Image Figure 6. Global Microbiome Drugs Market Size Growth Rate by Symptom (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Microbiome Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 8. Gastrointestinal Disorders Image Figure 9. Autoimmune Disorders Image Figure 10. Diabetes Image Figure 11. Cancer Image Figure 12. Others Image Figure 13. Global Microbiome Drugs Market Size (US$ Million) & (2021-2032) Figure 14. Global Microbiome Drugs Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Microbiome Drugs Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Microbiome Drugs Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Microbiome Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Microbiome Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Microbiome Drugs Revenue Market Share by Type (2021-2032) Figure 21. Global Microbiome Drugs Revenue by Symptom (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Microbiome Drugs Revenue Market Share by Symptom (2021 VS 2025 VS 2032) Figure 23. Global Microbiome Drugs Revenue Market Share by Symptom (2021-2032) Figure 24. North America Microbiome Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Microbiome Drugs Revenue Share by Type (2021-2032) Figure 26. North America Microbiome Drugs Revenue Share by Application (2021-2032) Figure 27. North America Microbiome Drugs Revenue Share by Country (2021-2032) Figure 28. United States Microbiome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Microbiome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Microbiome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Microbiome Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Microbiome Drugs Revenue Share by Type (2021-2032) Figure 33. Europe Microbiome Drugs Revenue Share by Application (2021-2032) Figure 34. Europe Microbiome Drugs Revenue Share by Country (2021-2032) Figure 35. Germany Microbiome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Microbiome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Microbiome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Microbiome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Microbiome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Microbiome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Microbiome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Microbiome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Microbiome Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Microbiome Drugs Revenue Share by Type (2021-2032) Figure 45. China Microbiome Drugs Revenue Share by Application (2021-2032) Figure 46. Asia Microbiome Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Microbiome Drugs Revenue Share by Type (2021-2032) Figure 48. Asia Microbiome Drugs Revenue Share by Application (2021-2032) Figure 49. Asia Microbiome Drugs Revenue Share by Region (2021-2032) Figure 50. Japan Microbiome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Microbiome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Microbiome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Microbiome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Microbiome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Microbiome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Microbiome Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Microbiome Drugs Revenue Share by Type (2021-2032) Figure 58. SAMEA Microbiome Drugs Revenue Share by Application (2021-2032) Figure 59. SAMEA Microbiome Drugs Revenue Share by Country (2021-2032) Figure 60. Brazil Microbiome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Microbiome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Microbiome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Microbiome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Microbiome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Microbiome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Microbiome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Microbiome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Microbiome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Microbiome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Microbiome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Oral Dosage Form
  • Enteric Capsules
Applications
  • Gastrointestinal Disorders
  • Autoimmune Disorders
  • Diabetes
  • Cancer
  • Others
Companies covered
  • Seres Therapeutics
  • Assembly Biosciences
  • Synthetic Biologics
  • Interxon
  • PureTech
  • Synlogic
  • Enterome BioScience
  • 4D Pharma
  • Second Genome
  • AOBiome
  • Rebiotix
  • Metabiomics
  • Ritter Pharmaceuticals
  • Symberix
  • OpenBiome
  • Azitra
  • Osel

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Microbiome Drugs Market by Type
  3. 1.2.1 Global Microbiome Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Oral Dosage Form
  5. 1.2.3 Enteric Capsules
  6. 1.3 Microbiome Drugs Market by Symptom
  7. 1.3.1 Global Microbiome Drugs Market Size by Symptom, 2021 VS 2025 VS 2032
  8. 1.3.2 Gastrointestinal Disorders
  9. 1.3.3 Autoimmune Disorders
  10. 1.3.4 Diabetes
  11. 1.3.5 Cancer
  12. 1.3.6 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Microbiome Drugs Market Dynamics
  1. 2.1 Microbiome Drugs Industry Trends
  2. 2.2 Microbiome Drugs Industry Drivers
  3. 2.3 Microbiome Drugs Industry Opportunities and Challenges
  4. 2.4 Microbiome Drugs Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Microbiome Drugs Market Perspective (2021-2032)
  2. 3.2 Global Microbiome Drugs Growth Trends by Region
  3. 3.2.1 Global Microbiome Drugs Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Microbiome Drugs Market Size by Region (2021-2026)
  5. 3.2.3 Global Microbiome Drugs Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Microbiome Drugs Revenue by Players
  2. 4.1.1 Global Microbiome Drugs Revenue by Players (2021-2026)
  3. 4.1.2 Global Microbiome Drugs Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Microbiome Drugs Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Microbiome Drugs Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Microbiome Drugs Key Players Headquarters & Area Served
  7. 4.4 Global Microbiome Drugs Players, Product Type & Application
  8. 4.5 Global Microbiome Drugs Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Microbiome Drugs Market CR5 and HHI
  11. 4.6.3 2025 Microbiome Drugs Tier 1, Tier 2, and Tier 3
5 Microbiome Drugs Market Size by Type
  1. 5.1 Global Microbiome Drugs Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Microbiome Drugs Revenue by Type (2021-2032)
  3. 5.3 Global Microbiome Drugs Revenue Market Share by Type (2021-2032)
6 Microbiome Drugs Market Size by Application
  1. 6.1 Global Microbiome Drugs Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Microbiome Drugs Revenue by Application (2021-2032)
  3. 6.3 Global Microbiome Drugs Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Seres Therapeutics
  2. 7.1.1 Seres Therapeutics Company Information
  3. 7.1.2 Seres Therapeutics Business Overview
  4. 7.1.3 Seres Therapeutics Microbiome Drugs Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Seres Therapeutics Microbiome Drugs Product Portfolio
  6. 7.1.5 Seres Therapeutics Recent Developments
  7. 7.2 Assembly Biosciences
  8. 7.2.1 Assembly Biosciences Company Information
  9. 7.2.2 Assembly Biosciences Business Overview
  10. 7.2.3 Assembly Biosciences Microbiome Drugs Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Assembly Biosciences Microbiome Drugs Product Portfolio
  12. 7.2.5 Assembly Biosciences Recent Developments
  13. 7.3 Synthetic Biologics
  14. 7.3.1 Synthetic Biologics Company Information
  15. 7.3.2 Synthetic Biologics Business Overview
  16. 7.3.3 Synthetic Biologics Microbiome Drugs Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Synthetic Biologics Microbiome Drugs Product Portfolio
  18. 7.3.5 Synthetic Biologics Recent Developments
  19. 7.4 Interxon
  20. 7.4.1 Interxon Company Information
  21. 7.4.2 Interxon Business Overview
  22. 7.4.3 Interxon Microbiome Drugs Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Interxon Microbiome Drugs Product Portfolio
  24. 7.4.5 Interxon Recent Developments
  25. 7.5 PureTech
  26. 7.5.1 PureTech Company Information
  27. 7.5.2 PureTech Business Overview
  28. 7.5.3 PureTech Microbiome Drugs Revenue and Gross Margin (2021-2026)
  29. 7.5.4 PureTech Microbiome Drugs Product Portfolio
  30. 7.5.5 PureTech Recent Developments
  31. 7.6 Synlogic
  32. 7.6.1 Synlogic Company Information
  33. 7.6.2 Synlogic Business Overview
  34. 7.6.3 Synlogic Microbiome Drugs Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Synlogic Microbiome Drugs Product Portfolio
  36. 7.6.5 Synlogic Recent Developments
  37. 7.7 Enterome BioScience
  38. 7.7.1 Enterome BioScience Company Information
  39. 7.7.2 Enterome BioScience Business Overview
  40. 7.7.3 Enterome BioScience Microbiome Drugs Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Enterome BioScience Microbiome Drugs Product Portfolio
  42. 7.7.5 Enterome BioScience Recent Developments
  43. 7.8 4D Pharma
  44. 7.8.1 4D Pharma Company Information
  45. 7.8.2 4D Pharma Business Overview
  46. 7.8.3 4D Pharma Microbiome Drugs Revenue and Gross Margin (2021-2026)
  47. 7.8.4 4D Pharma Microbiome Drugs Product Portfolio
  48. 7.8.5 4D Pharma Recent Developments
  49. 7.9 Second Genome
  50. 7.9.1 Second Genome Company Information
  51. 7.9.2 Second Genome Business Overview
  52. 7.9.3 Second Genome Microbiome Drugs Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Second Genome Microbiome Drugs Product Portfolio
  54. 7.9.5 Second Genome Recent Developments
  55. 7.10 AOBiome
  56. 7.10.1 AOBiome Company Information
  57. 7.10.2 AOBiome Business Overview
  58. 7.10.3 AOBiome Microbiome Drugs Revenue and Gross Margin (2021-2026)
  59. 7.10.4 AOBiome Microbiome Drugs Product Portfolio
  60. 7.10.5 AOBiome Recent Developments
  61. 7.11 Rebiotix
  62. 7.11.1 Rebiotix Company Information
  63. 7.11.2 Rebiotix Business Overview
  64. 7.11.3 Rebiotix Microbiome Drugs Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Rebiotix Microbiome Drugs Product Portfolio
  66. 7.11.5 Rebiotix Recent Developments
  67. 7.12 Metabiomics
  68. 7.12.1 Metabiomics Company Information
  69. 7.12.2 Metabiomics Business Overview
  70. 7.12.3 Metabiomics Microbiome Drugs Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Metabiomics Microbiome Drugs Product Portfolio
  72. 7.12.5 Metabiomics Recent Developments
  73. 7.13 Ritter Pharmaceuticals
  74. 7.13.1 Ritter Pharmaceuticals Company Information
  75. 7.13.2 Ritter Pharmaceuticals Business Overview
  76. 7.13.3 Ritter Pharmaceuticals Microbiome Drugs Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Ritter Pharmaceuticals Microbiome Drugs Product Portfolio
  78. 7.13.5 Ritter Pharmaceuticals Recent Developments
  79. 7.14 Symberix
  80. 7.14.1 Symberix Company Information
  81. 7.14.2 Symberix Business Overview
  82. 7.14.3 Symberix Microbiome Drugs Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Symberix Microbiome Drugs Product Portfolio
  84. 7.14.5 Symberix Recent Developments
  85. 7.15 OpenBiome
  86. 7.15.1 OpenBiome Company Information
  87. 7.15.2 OpenBiome Business Overview
  88. 7.15.3 OpenBiome Microbiome Drugs Revenue and Gross Margin (2021-2026)
  89. 7.15.4 OpenBiome Microbiome Drugs Product Portfolio
  90. 7.15.5 OpenBiome Recent Developments
  91. 7.16 Azitra
  92. 7.16.1 Azitra Company Information
  93. 7.16.2 Azitra Business Overview
  94. 7.16.3 Azitra Microbiome Drugs Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Azitra Microbiome Drugs Product Portfolio
  96. 7.16.5 Azitra Recent Developments
  97. 7.17 Osel
  98. 7.17.1 Osel Company Information
  99. 7.17.2 Osel Business Overview
  100. 7.17.3 Osel Microbiome Drugs Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Osel Microbiome Drugs Product Portfolio
  102. 7.17.5 Osel Recent Developments
8 North America
  1. 8.1 North America Microbiome Drugs Revenue (2021-2032)
  2. 8.2 North America Microbiome Drugs Revenue by Type (2021-2032)
  3. 8.2.1 North America Microbiome Drugs Revenue by Type (2021-2026)
  4. 8.2.2 North America Microbiome Drugs Revenue by Type (2027-2032)
  5. 8.3 North America Microbiome Drugs Revenue Share by Type (2021-2032)
  6. 8.4 North America Microbiome Drugs Revenue by Symptom (2021-2032)
  7. 8.4.1 North America Microbiome Drugs Revenue by Symptom (2021-2026)
  8. 8.4.2 North America Microbiome Drugs Revenue by Symptom (2027-2032)
  9. 8.5 North America Microbiome Drugs Revenue Share by Symptom (2021-2032)
  10. 8.6 North America Microbiome Drugs Revenue by Country
  11. 8.6.1 North America Microbiome Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Microbiome Drugs Revenue by Country (2021-2026)
  13. 8.6.3 North America Microbiome Drugs Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Microbiome Drugs Revenue (2021-2032)
  2. 9.2 Europe Microbiome Drugs Revenue by Type (2021-2032)
  3. 9.2.1 Europe Microbiome Drugs Revenue by Type (2021-2026)
  4. 9.2.2 Europe Microbiome Drugs Revenue by Type (2027-2032)
  5. 9.3 Europe Microbiome Drugs Revenue Share by Type (2021-2032)
  6. 9.4 Europe Microbiome Drugs Revenue by Symptom (2021-2032)
  7. 9.4.1 Europe Microbiome Drugs Revenue by Symptom (2021-2026)
  8. 9.4.2 Europe Microbiome Drugs Revenue by Symptom (2027-2032)
  9. 9.5 Europe Microbiome Drugs Revenue Share by Symptom (2021-2032)
  10. 9.6 Europe Microbiome Drugs Revenue by Country
  11. 9.6.1 Europe Microbiome Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Microbiome Drugs Revenue by Country (2021-2026)
  13. 9.6.3 Europe Microbiome Drugs Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Microbiome Drugs Revenue (2021-2032)
  2. 10.2 China Microbiome Drugs Revenue by Type (2021-2032)
  3. 10.2.1 China Microbiome Drugs Revenue by Type (2021-2026)
  4. 10.2.2 China Microbiome Drugs Revenue by Type (2027-2032)
  5. 10.3 China Microbiome Drugs Revenue Share by Type (2021-2032)
  6. 10.4 China Microbiome Drugs Revenue by Symptom (2021-2032)
  7. 10.4.1 China Microbiome Drugs Revenue by Symptom (2021-2026)
  8. 10.4.2 China Microbiome Drugs Revenue by Symptom (2027-2032)
  9. 10.5 China Microbiome Drugs Revenue Share by Symptom (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Microbiome Drugs Revenue (2021-2032)
  2. 11.2 Asia Microbiome Drugs Revenue by Type (2021-2032)
  3. 11.2.1 Asia Microbiome Drugs Revenue by Type (2021-2026)
  4. 11.2.2 Asia Microbiome Drugs Revenue by Type (2027-2032)
  5. 11.3 Asia Microbiome Drugs Revenue Share by Type (2021-2032)
  6. 11.4 Asia Microbiome Drugs Revenue by Symptom (2021-2032)
  7. 11.4.1 Asia Microbiome Drugs Revenue by Symptom (2021-2026)
  8. 11.4.2 Asia Microbiome Drugs Revenue by Symptom (2027-2032)
  9. 11.5 Asia Microbiome Drugs Revenue Share by Symptom (2021-2032)
  10. 11.6 Asia Microbiome Drugs Revenue by Country
  11. 11.6.1 Asia Microbiome Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Microbiome Drugs Revenue by Country (2021-2026)
  13. 11.6.3 Asia Microbiome Drugs Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Microbiome Drugs Revenue (2021-2032)
  2. 12.2 SAMEA Microbiome Drugs Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Microbiome Drugs Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Microbiome Drugs Revenue by Type (2027-2032)
  5. 12.3 SAMEA Microbiome Drugs Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Microbiome Drugs Revenue by Symptom (2021-2032)
  7. 12.4.1 SAMEA Microbiome Drugs Revenue by Symptom (2021-2026)
  8. 12.4.2 SAMEA Microbiome Drugs Revenue by Symptom (2027-2032)
  9. 12.5 SAMEA Microbiome Drugs Revenue Share by Symptom (2021-2032)
  10. 12.6 SAMEA Microbiome Drugs Revenue by Country
  11. 12.6.1 SAMEA Microbiome Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Microbiome Drugs Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Microbiome Drugs Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst